Pandect Bioventures
Pandect Bioventures is a venture capital firm focused on providing seed to Series A and later funding to early-stage biotech and pharma companies. The firm leverages its extensive ecosystem, including a 40,000 square foot incubator facility, to support entrepreneurs in achieving critical business milestones. Pandect Bioventures is committed to identifying transformational healthcare ideas at the earliest stage and building them into successful life science companies through strategic partnerships, financial and technical support, and access to state-of-the-art research facilities.
Pandect Bioventures
What We Do
Pandect Bioventures provides seed, Series A, and later-round funding for startups, assessed through a rigorous process.
Access to a 40,000 square foot incubator facility in South San Francisco, offering a fertile ground for growing and cultivating investment opportunities.
Top academic and industry advisors bring experience from every stage of company formation and growth, from management teams to identifying disease targets.
Exclusive relationships with research institutions provide unique access to emerging discoveries, top advisors, intellectual property, and research infrastructure.
Onsite CRO services for research and technical support, supported by technical advisory staff.
Portfolio
Developing a new paradigm for cell permeable macrocyclic peptide discovery. Co-invested with The Column Group and Nextech Invest in 2020.
#Oncology
Formed an oncology newco at the ShangPharma incubator with a UCSF co-founder. Led the Seed round in 2020.
#Oncology
Biotech spin-out from the University of California, Berkeley. Co-led Series A in 2019.
#Ophthalmology
Leader in B cell medicines, co-invested with The Emerson Collective in 2021.
#Oncology
Applying a systems-based approach to understand kidney disease. Co-invested with Arch Venture Partners in 2020.
#Nephrology
Key People
Managing Director
Managing Director
Managing Director